Skip to content
    Eli Lilly and Company logo

    Eli Lilly and Company

    Indianapolis, Indiana, United States
    www.lilly.com
    Biotech & Life SciencesHealthcare

    Eli Lilly and Company's venture capital efforts, primarily through Lilly Ventures, focus on investing in early to expansion-stage life sciences companies across biotechnology, medical devices, and diagnostics, aiming to foster innovation and provide strategic resources. Additionally, they have a Social Impact Venture Capital Portfolio dedicated to improving healthcare access for underserved communities and a new Biotech Ecosystem Venture Fund with Andreessen Horowitz to advance therapeutic platforms and cutting-edge health technologies.

    83% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $67.8M (across 20 rounds with reported amounts).

    Find people at Eli Lilly and Company on Goldilocks AI

    Portfolio

    23

    Fund Size

    $175M

    Top Stage

    Series A

    Last 12 Mo

    6

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    23 investments
    CompanyRoundAmountDate
    TTRexBioSeries C$50MJan 2026
    Juvena Therapeutics logoJuvena TherapeuticsSeries B$33.5MJan 2026
    Recludix Pharma logoRecludix PharmaUnknown—Jan 2026
    Gate Bioscience logoGate BioscienceSeries B$65MNov 2025
    Trogenix logoTrogenixSeries A$80MOct 2025
    Dualitas Therapeutics, Inc. logoDualitas Therapeutics, Inc.Series A$65MSep 2025
    Solu Therapeutics logoSolu TherapeuticsSeries A$41MApr 2025
    AAugustine TherapeuticsSeries A$77.7MMar 2025
    Elektrofi, Inc. logoElektrofi, Inc.Series C$112.3MOct 2024
    Aktis Oncology logoAktis OncologySeries B$175MSep 2024
    NNanoSyrinxUnknown$12.7MSep 2024
    RetiSpec Inc. logoRetiSpec Inc.Series A$10MJul 2024
    Lycia Therapeutics, Inc. logoLycia Therapeutics, Inc.Series C$106.6MMay 2024
    ViaNautis Bio logoViaNautis BioSeries A$25MNov 2023
    Flare Therapeutics Inc. logoFlare Therapeutics Inc.Series B$123MMar 2023
    PrescriberPoint logoPrescriberPointSeed—Jan 2023
    Auron Therapeutics logoAuron TherapeuticsSeries A$48MJul 2022
    Arkuda Therapeutics logoArkuda TherapeuticsSeries B$64MFeb 2022
    FFoghorn TherapeuticsSeries C$80MDec 2021
    DTx Pharma logoDTx PharmaSeries B$100MMar 2021
    Seraxis logoSeraxisSeries C$40MFeb 2021
    PPetra Pharma CorporationSeries A$48MJan 2016
    Sigilon Therapeutics logoSigilon TherapeuticsUnknown——

    Top Co-Investors

    Alexandria Venture Investments6 shared
    Janus Henderson Investors5 shared
    Pfizer Ventures4 shared
    Polaris Venture Partners3 shared
    RA Capital Management3 shared
    Casdin Capital2 shared
    Invus2 shared
    BGF2 shared
    Versant Ventures2 shared
    ARCH Venture Partners2 shared
    DCVC2 shared
    Access Biotechnology2 shared
    Cormorant Asset Management2 shared
    Surveyor Capital2 shared
    IQ Capital2 shared
    Qiming Venture Partners USA2 shared
    SV Health Investors2 shared
    Logos Capital2 shared
    Novo Holdings2 shared
    RTW Investments2 shared

    Last updated: 16 April 2026